Hot Features
Premium
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 14,546 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Marinus Pharmaceuticals Inc | MRNS | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 1.40 | 07:44:49 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 1.40 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 121 | 14,546 | - | 1.11 - 11.26 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 08:09:42 | formt | 529 | US$ 1.40 | USD |
Marinus Pharmaceuticals Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 76.5M | 54.64M | - | 30.99M | -141.41M | -2.59 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Marinus Pharmaceuticals News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MRNS Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.45 | 1.56 | 1.37 | 1.43 | 1,572,861 | -0.05 | -3.45% |
| 1 Month | 8.86 | 9.03 | 1.11 | 1.75 | 4,420,568 | -7.46 | -84.20% |
| 3 Months | 9.91 | 10.50 | 1.11 | 2.98 | 1,818,338 | -8.51 | -85.87% |
| 6 Months | 6.65 | 11.26 | 1.11 | 4.20 | 1,074,501 | -5.25 | -78.95% |
| 1 Year | 9.09 | 11.26 | 1.11 | 5.97 | 917,470 | -7.69 | -84.60% |
| 3 Years | 14.75 | 19.83 | 1.11 | 6.90 | 518,746 | -13.35 | -90.51% |
| 5 Years | 5.15 | 20.04 | 0.77 | 4.52 | 1,023,212 | -3.75 | -72.82% |
Marinus Pharmaceuticals Description
| Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19 pediatric epilepsy. |
